Direct comparison of transcardiac increase in Brain Natriuretic Peptide (BNP) and N-terminal ProBNP and prognosis in patients with chronic heart failure

Circulation Journal

Volumn 71, Issue 12, 2007, Pages 1873-1878

  Tsutamoto, Takayoshi ^a   Sakai, Hiroshi ^a   Nishiyama, Keizo ^a   Tanaka, Toshinari ^a   Fujii, Masanori ^a   Yamamoto, Takashi ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Brain natriuretic peptide; Heart failure; N terminal pro brain natriuretic peptide; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

ADULT; AORTA ROOT; ARTICLE; CONTROLLED STUDY; CORONARY SINUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AORTA; BIOLOGICAL MARKERS; CHRONIC DISEASE; CORONARY SINUS; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; VENTRICULAR DYSFUNCTION, LEFT;

EID: 37149042063     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1873     Document Type: Article

References (23)

1. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
2. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T. et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-1593.
3. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-1283.
4. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction: Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37: 1781-1787.
5. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide: A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24: 1735-1743.
6. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. NT-proBNP in severe chronic heart failure: Rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 2004; 6: 343-350.
7. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39: 571-588.
8. Hunt PJ, Richards AM, Nicholls MG, Yandel TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocrinol 1997; 47: 287-296.
9. Tateyama H, Hino J, Minamino N, Kangawa K, Minamino T, Sakai K, et al. Concentrations and molecular forms of human brain natriuretic peptide in plasma. Biochem Biophys Res Commun 1992; 185: 760-767.
10. Tsutamoto T, Sakai J, Ishikawa C, Fujii M, Yamamoto T, Wada A, et al. Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal proBNP in patients with chronic heart failure. Eur J Heart Fail 2007; 9: 667-673.
11. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002; 316: 129-135.
12. Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci 2005; 102: 17442-17447.
13. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) Data. Clin Chem 2006; 52: 1528-1538.
14. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: Relationship between renal function and left ventricular hypertrophy. Am J Kidney Dis 2006; 46: 610-620.
15. Hall C. NT-ProBNP: The mechanism behind the marker. J Card Fail 2005; 11: S81-S83.
16. Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006; 47: 582-586.
17. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 838-844.
18. Alehagen U, Lindstedt G, Levin LA, Dahlstrom U. Risk of cardiovascular death in elderly patients with possible heart failure: B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population. Int J Cardiol 2005; 100: 125-133.
19. Hulsmann M, Berger R, Mortl D, Gore O, Meyer B, Pacher R. Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: A direct comparison of N-terminal atrial natriuretic peptide. N-terminal brain natriuretic peptide and brain natriuretic peptide. Eur J Heart Fail 2005; 7: 552-556.
20. Fischer Y, Filzmaier K, Stiegler H, Graf J, Fuhs S, Franke A, et al. Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide. Clin Chem 2001; 47: 591-594.
21. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practices: The need for a new generation of immunoassay methods. Clin Chem 2000; 46: 1529-1534.
22. McCullough PA, Duc P, Omland T, McCord J, Nowak RM. Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 4: 571-579.
23. Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005; 46: 118-123.